Ad hoc announcement pursuant to Art. 53 LR
ENIGMA-TRS 1 is an international, one-year, double-blind, placebo-controlled Phase III study in at least 600 patients; 12-week study
Ad hoc announcement pursuant to Art. 53 LR
New findings published in Neuropsychopharmacology are the first to demonstrate that evenamide targets the key site of schizophrenia
Ad hoc announcement pursuant to Art. 53 LR
ENIGMA-TRS 1 is an international, one-year, double-blind, placebo-controlled Phase III study in at least 600 patients; enrollment
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, April 23, 2025, 11:30 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, April 1, 2025, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical
Ad hoc announcement pursuant to Art. 53 LR
Expected to succeed Dr. Ulrich Köstlin who has notified Newron of his intention to retire after 12 years of service as Chairman of its
Milan, Italy and Morristown, NJ, USA – March 11, 2025 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused
Newron and Myung In Pharm announce license agreement for evenamide in South Korea
Myung In Pharm to develop, manufacture and commercialize evenamide in South Korea
Myung In Pharm
Ad hoc announcement pursuant to Art. 53 LR
Newron will receive up to a maximum of €117 million from an upfront payment, development milestones and commercialization milestones,
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, September 19, 2024, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
